Zacks.com on MSN4d
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority TagThe FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
GlobalData on MSN5d
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseasesApellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...
Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Empaveli (pegcetacoplan) for two rare and severe ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...
(RTTNews) - Apellis Pharmaceuticals, Inc. (APLS) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the supplemental New Drug Application ...
Hello, and welcome to Sonida Senior Living Fourth and Full Year 2024 Earnings Call. Please note that this call is being recorded. After the speakers’ prepared remarks, there will be a question ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback